Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults.
Christine Durier
(1)
,
Corinne Desaint
(2)
,
Frédéric Lucht
(3)
,
Pierre-Marie Girard
,
Yves Lévy
(4)
,
Thierry May
(5)
,
Christian Michelet
(6)
,
Agathe Rami
,
François Roman
,
Jean-François Delfraissy
(7)
,
Jean-Pierre Aboulker
(1)
,
Odile Launay
(2)
1
Essais Therapeutiques et Infection Par Le Vih
2 CIC - Biotherapie - AP-HP (cochin - Pasteur)
3 GIMAP - Groupe Immunité des Muqueuses et Agents Pathogènes
4 IMRB - Institut Mondor de Recherche Biomédicale
5 Service des Maladies Infectieuses et Tropicales [CHRU Nancy]
6 Irset - Institut de recherche en santé, environnement et travail
7 Service de médecine interne et maladies infectieuses
2 CIC - Biotherapie - AP-HP (cochin - Pasteur)
3 GIMAP - Groupe Immunité des Muqueuses et Agents Pathogènes
4 IMRB - Institut Mondor de Recherche Biomédicale
5 Service des Maladies Infectieuses et Tropicales [CHRU Nancy]
6 Irset - Institut de recherche en santé, environnement et travail
7 Service de médecine interne et maladies infectieuses
Pierre-Marie Girard
- Fonction : Auteur
Yves Lévy
- Fonction : Auteur
- PersonId : 759951
- ORCID : 0000-0002-4224-3137
Agathe Rami
- Fonction : Auteur
François Roman
- Fonction : Auteur
Odile Launay
Connectez-vous pour contacter l'auteur
- Fonction : Auteur correspondant
- PersonId : 907445
Connectez-vous pour contacter l'auteur
Résumé
OBJECTIVE: In immunocompromised patients, alternative schedules more immunogenic than the standard influenza vaccine regimen are necessary to enhance and prolong vaccine efficacy. We previously reported that the AS03A-adjuvanted 2009 A/H1N1v vaccine yielded a higher short-term immune response than the nonadjuvanted one in HIV-1-infected adults. This study reports the long-term persistence of the immune response. DESIGN AND METHODS: In a prospective, multicenter, randomized, patient-blinded trial, two doses of AS03A-adjuvanted H1N1v vaccine containing 3.75 μg haemagglutinin (n = 155; group A) or nonadjuvanted H1N1v vaccine containing 15 μg haemagglutinin (n = 151; group B), were administered 21 days apart. Haemagglutination inhibition and neutralizing antibodies were assessed 6 and 12 months after vaccination. RESULTS: In group A and B, the seroprotection rates were 83.7 and 59.4% at month 6, and 70.4 and 49.3 at month 12, respectively. In a multivariate analysis, persistence of seroprotection 12 months after vaccination was negatively associated with current smoking (odds ratio = 0.6, P = 0.03) and positively related with the AS03A-adjuvanted H1N1v vaccine (odds ratio = 2.7, P = 0.0002). CONCLUSION: In HIV-1-infected adults, two doses of adjuvanted influenza vaccine induce long-term persistence of immune response up to 1 year after vaccination.
Domaines
VaccinologieFormat du dépôt | Notice |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults.
|
Résumé |
en
OBJECTIVE: In immunocompromised patients, alternative schedules more immunogenic than the standard influenza vaccine regimen are necessary to enhance and prolong vaccine efficacy. We previously reported that the AS03A-adjuvanted 2009 A/H1N1v vaccine yielded a higher short-term immune response than the nonadjuvanted one in HIV-1-infected adults. This study reports the long-term persistence of the immune response. DESIGN AND METHODS: In a prospective, multicenter, randomized, patient-blinded trial, two doses of AS03A-adjuvanted H1N1v vaccine containing 3.75 μg haemagglutinin (n = 155; group A) or nonadjuvanted H1N1v vaccine containing 15 μg haemagglutinin (n = 151; group B), were administered 21 days apart. Haemagglutination inhibition and neutralizing antibodies were assessed 6 and 12 months after vaccination. RESULTS: In group A and B, the seroprotection rates were 83.7 and 59.4% at month 6, and 70.4 and 49.3 at month 12, respectively. In a multivariate analysis, persistence of seroprotection 12 months after vaccination was negatively associated with current smoking (odds ratio = 0.6, P = 0.03) and positively related with the AS03A-adjuvanted H1N1v vaccine (odds ratio = 2.7, P = 0.0002). CONCLUSION: In HIV-1-infected adults, two doses of adjuvanted influenza vaccine induce long-term persistence of immune response up to 1 year after vaccination.
|
Auteur(s) |
Christine Durier
1
, Corinne Desaint
2
, Frédéric Lucht
3
, Pierre-Marie Girard
, Yves Lévy
4
, Thierry May
5
, Christian Michelet
6
, Agathe Rami
, François Roman
, Jean-François Delfraissy
7
, Jean-Pierre Aboulker
1
, Odile Launay
2
1
Essais Therapeutiques et Infection Par Le Vih
( 2794 )
- Centre de Recherche Inserm PARIS XI 16, Avenue Paul Vaillant-Couturier 94807 VILLEJUIF CEDEX
- France
2
CIC - Biotherapie - AP-HP (cochin - Pasteur)
( 2593 )
- Hopital Cochin PARIS V 27, Rue du Faubourg Saint-Jacques 75679 PARIS CEDEX 14
- France
3
GIMAP -
Groupe Immunité des Muqueuses et Agents Pathogènes
( 3137 )
- France
4
IMRB -
Institut Mondor de Recherche Biomédicale
( 266797 )
- 8 rue du Général Sarrail 94010 Créteil
- France
5
Service des Maladies Infectieuses et Tropicales [CHRU Nancy]
( 245658 )
- Vandœuvre-lès-Nancy
- France
6
Irset -
Institut de recherche en santé, environnement et travail
( 182194 )
- 263 avenue Général Leclerc 35042 Rennes Cedex
- France
7
Service de médecine interne et maladies infectieuses
( 33891 )
- Le Kremlin-Bicêtre
- France
|
Audience |
Internationale
|
Date de publication |
2013-01-02
|
Volume |
27
|
Numéro |
1
|
Page/Identifiant |
87-93
|
Comité de lecture |
Oui
|
Vulgarisation |
Non
|
Langue du document |
Anglais
|
Nom de la revue |
|
Financement |
|
Domaine(s) |
|
Collaboration/Projet |
|
Mots-clés (Mesh) |
|
DOI | 10.1097/QAD.0b013e328359f27a |
Pubmed Id | 23018437 |
Loading...